Metastatic or Locally Advanced Breast Cancer (DBCOND0039542)

Identifiers

Synonyms

Locally Advanced or Metastatic Breast Cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Capivasertib	A serine/threonine kinase inhibitor used to treat hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Cytochrome P450 3A4enzyme UDP-glucuronosyltransferase 2B7enzyme RAC-alpha serine/threonine-protein kinasetarget RAC-beta serine/threonine-protein kinasetarget RAC-gamma serine/threonine-protein kinasetarget Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Organic anion transporter 3transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Solute carrier family 22 member 2transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00637325	Trastuzumab Optimization Trial in Breast Cancer	Trastuzumab	treatment	3	unknown_status
NCT05744687	Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer	N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo(d)imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-amine	treatment	2 / 3	recruiting
NCT03437083	A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants	Eribulin	Not Available	Not Available	completed
NCT05430399	Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer	Docetaxel Utidelone	treatment	3	recruiting
NCT05172518	Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer	Capecitabine Utidelone	treatment	3	not_yet_recruiting
NCT03781063	Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Fulvestrant Lasofoxifene	treatment	2	active_not_recruiting
NCT05860465	Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer	N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo(d)imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl)-5,6,7,8-tetrahydro-l,6-naphthyridin-2-amine	treatment	2 / 3	recruiting
NCT05403333	Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer	No drug interventions	treatment	2	not_yet_recruiting
NCT05054751	GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	No drug interventions	treatment	3	unknown_status
NCT03027245	Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy	No drug interventions	Not Available	Not Available	completed
NCT05296798	A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)	No drug interventions	treatment	3	recruiting
NCT06439771	A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC	No drug interventions	treatment	2	active_not_recruiting
NCT00634088	Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer	No drug interventions	treatment	1	terminated
NCT05212701	To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer	No drug interventions	treatment	2	withdrawn